798 related articles for article (PubMed ID: 33944642)
1. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Keeling S; Maksymowych WP
Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
[TBL] [Abstract][Full Text] [Related]
2. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J; Kiltz U; Baraliakos X
Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
[TBL] [Abstract][Full Text] [Related]
3. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
[TBL] [Abstract][Full Text] [Related]
4. The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials.
Denis A; Sztejkowski C; Arnaud L; Becker G; Felten R
RMD Open; 2023 Jul; 9(3):. PubMed ID: 37507210
[TBL] [Abstract][Full Text] [Related]
5. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
[TBL] [Abstract][Full Text] [Related]
6. Recent developments for new investigational JAK inhibitors in psoriatic arthritis.
Caso F; Costa L; Triggianese P; Maione F; Bertolini N; Vastarella M; Chimenti MS; Tasso M
Expert Opin Investig Drugs; 2023 May; 32(5):361-371. PubMed ID: 37096862
[TBL] [Abstract][Full Text] [Related]
7. JAK inhibition in the treatment of inflammatory rheumatic diseases.
Šenolt L
Vnitr Lek; 2023; 69(3):181-188. PubMed ID: 37468313
[TBL] [Abstract][Full Text] [Related]
8. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
[TBL] [Abstract][Full Text] [Related]
9. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
Chen M; Dai SM
Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
[TBL] [Abstract][Full Text] [Related]
10. Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2023 Jun; 82(5):408-416. PubMed ID: 34716775
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis.
Braun J; Kiltz U; Baraliakos X
Expert Opin Biol Ther; 2023 Feb; 23(2):195-206. PubMed ID: 36511882
[TBL] [Abstract][Full Text] [Related]
12. The role of upadacitinib for the treatment of axial spondyloarthritis.
George N; Liew JW; Dubreuil M
Immunotherapy; 2023 Oct; 15(15):1227-1237. PubMed ID: 37675498
[TBL] [Abstract][Full Text] [Related]
13. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
[TBL] [Abstract][Full Text] [Related]
14. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.
Lee YH; Song GG
Pharmacology; 2023; 108(6):589-598. PubMed ID: 37591216
[TBL] [Abstract][Full Text] [Related]
15. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib for the treatment of active ankylosing spondylitis in adults.
Mohanakrishnan R; Beier S; Deodhar A
Expert Rev Clin Immunol; 2022 Mar; 18(3):273-280. PubMed ID: 35152808
[TBL] [Abstract][Full Text] [Related]
17. Targeted and biological drugs in the treatment of inflammatory rheumatic diseases.
Pavelka K
Vnitr Lek; 2021; 67(4):195-200. PubMed ID: 34275303
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of JAK inhibitors on enthesitis in spondyloarthropathy: A scoping literature review.
Jubber A; Tahir H; Moorthy A
Musculoskeletal Care; 2023 Dec; 21(4):1195-1203. PubMed ID: 37501580
[TBL] [Abstract][Full Text] [Related]
19. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Hammitzsch A; Lorenz G; Moog P
Front Immunol; 2020; 11():591176. PubMed ID: 33193430
[TBL] [Abstract][Full Text] [Related]
20. Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art.
Caso F; Navarini L; Ruscitti P; Chimenti MS; Girolimetto N; Del Puente A; Giacomelli R; Scarpa R; Costa L
Expert Opin Pharmacother; 2020 May; 21(7):785-796. PubMed ID: 32057269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
